# SGNTUC-019 (NCT04579380)

> Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

No report yet. It can be ordered.

- Drugs tested: tucatinib plus trastuzumab; tucatinib plus trastuzumab plus fulvestrant
- Indication: previously treated advanced solid tumors with HER2 alterations

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04579380
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Seagen, a wholly owned subsidiary of Pfizer
- Conditions: Uterine Neoplasms; Uterine Cervical Neoplasms; Biliary Tract Neoplasms; Urologic Neoplasms; Carcinoma, Non-Small-Cell Lung; HER2 Mutations Breast Neoplasms
- Interventions: tucatinib; trastuzumab; fulvestrant
- Enrollment: 217
- Primary outcome: Confirmed Objective Response Rate (cORR) as Assessed by Investigator

## Indexed commentary on SGNTUC-019 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 19
- Podcasts: 3
- YouTube: 2

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=sgntuc-019-nct04579380

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04579380", "email": "<work email>"}; the inbox owner confirms by the emailed link.